This book dives deep into the financial side of cancer immunotherapy. It breaks down the costs of new treatments, comparing them to traditional methods.
Inside, you’ll find:
Chapter 1: Economic overview of immunotherapy, including cost analyses, funding, and global impact.
Chapter 2: The price of checkpoint inhibitors, financial aid, and long-term value.
Chapter 3: CAR T-cell therapy expenses, from production to insurance.
Chapter 4: Costs of developing cancer vaccines and their potential for prevention.
Chapters 5-11: Financial analyses of various immunotherapies, including oncolytic viruses, adoptive cell transfer, bispecific antibodies, and nanotechnology.
Chapter 12: Strategies to lower costs and improve global access to these life-saving treatments.
Essential reading for healthcare financiers, policymakers, and anyone treating cancer.
Über den Autor
I am bestselling author. I have proven technical skills (Google certifications) to deliver insightful books with ten years of business experience. I have written and published 400 books as per Goodreads record.
ORCID: https://orcid.org/0009-0004-8629-830X
[email protected]